Related Experiment Video
Updated: Dec 28, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
Anh-Thu Huynh Dang1, Vu-Uyen Tran2, Thanh-Truong Tran2
1University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh city, Vietnam.
Abstract:
Comprehensive profiling of actionable mutations in non-small cell lung cancer (NSCLC) is vital to guide targeted therapy, thereby improving the survival rate of patients. Despite the high incidence and mortality rate of NSCLC in Vietnam, the actionable mutation profiles of Vietnamese patients have not been thoroughly examined. Here, we employed massively parallel sequencing to identify alterations in major driver genes (EGFR, KRAS, NRAS, BRAF, ALK and ROS1) in 350 Vietnamese NSCLC patients. We showed that the Vietnamese NSCLC patients exhibited mutations most frequently in EGFR (35.4%) and KRAS (22.6%), followed by ALK (6.6%), ROS1 (3.1%), BRAF (2.3%) and NRAS (0.6%). Interestingly, the cohort of Vietnamese patients with advanced adenocarcinoma had higher prevalence of EGFR mutations than the Caucasian MSK-IMPACT cohort. Compared to the East Asian cohort, it had lower EGFR but higher KRAS mutation prevalence. We found that KRAS mutations were more commonly detected in male patients while EGFR mutations was more frequently found in female. Moreover, younger patients (<61 years) had higher genetic rearrangements in ALK or ROS1. In conclusions, our study revealed mutation profiles of 6 driver genes in the largest cohort of NSCLC patients in Vietnam to date, highlighting significant differences in mutation prevalence to other cohorts.
Insights
This study analyzed actionable mutations in 350 Vietnamese non-small cell lung cancer (NSCLC) patients. Vietnamese NSCLC patients show distinct EGFR and KRAS mutation profiles compared to other populations.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
- Targeted therapies require comprehensive profiling of actionable mutations for effective patient treatment.
- Limited data exists on actionable mutation profiles in Vietnamese NSCLC patients.
Purpose of the Study:
- To characterize the actionable mutation landscape in a large cohort of Vietnamese NSCLC patients.
- To compare these profiles with existing data from Caucasian and East Asian populations.
- To identify demographic correlations with specific driver gene alterations.
Main Methods:
- Massively parallel sequencing was used to analyze mutations in key driver genes: EGFR, KRAS, NRAS, BRAF, ALK, and ROS1.
- The study included 350 Vietnamese patients diagnosed with NSCLC.
- Mutation frequencies were statistically analyzed and compared across different demographic groups and geographical cohorts.
Main Results:
- EGFR mutations were most frequent (35.4%), followed by KRAS (22.6%), ALK (6.6%), ROS1 (3.1%), BRAF (2.3%), and NRAS (0.6%).
- Vietnamese advanced adenocarcinoma patients showed higher EGFR mutation prevalence than the Caucasian MSK-IMPACT cohort.
- KRAS mutations were more common in males, EGFR in females, and ALK/ROS1 rearrangements in younger patients (<61 years).
Conclusions:
- This study presents the most extensive analysis of 6 driver gene mutations in Vietnamese NSCLC patients to date.
- Significant differences in mutation prevalence were observed when compared to Caucasian and East Asian cohorts.
- Understanding these unique mutation profiles is crucial for optimizing targeted therapy strategies in Vietnam.
